Protective Effect of Carvacrol on Acute Lung Injury Induced by Lipopolysaccharide in Mice

Feng, Xiaowei; Jia, Aiqing

doi:10.1007/s10753-014-9833-1

Cited by 41 publications

(38 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Notably, the inflammation-dampening properties of exogenous carvacrol was not restricted to the intestinal tract, but could also be observed in extra-intestinal organs such as liver, kidneys and lungs as indicated by less distinct apoptosis and secretion of the pro-inflammatory cytokines TNF and IFN-γ in respective organs. In support, carvacrol has been shown to improve survival during LPS-induced endotoxinemia and acute lung injury in mice and to result in less distinct secretion of pro-inflammatory cytokines including TNF and IL-6 [53].…”

Section: Discussionmentioning

confidence: 96%

Carvacrol ameliorates acute campylobacteriosis in a clinical murine infection model

et al. 2020

View full text Add to dashboard Cite

Background: The prevalence of human infections with the zoonotic pathogen Campylobacter jejuni is rising worldwide. Therefore, the identification of compounds with potent anti-pathogenic and anti-inflammatory properties for future therapeutic and/or preventive application to combat campylobacteriosis is of importance for global health. Results of recent studies suggested carvacrol (4-isopropyl-2-methylphenol) as potential candidate molecule for the treatment of campylobacteriosis in humans and for the prevention of Campylobacter colonization in farm animals. Results:To address this in a clinical murine infection model of acute campylobacteriosis, secondary abiotic IL-10 −/− mice were subjected to synthetic carvacrol via the drinking water starting 4 days before peroral C. jejuni challenge. Whereas at day 6 post-infection placebo treated mice suffered from acute enterocolitis, mice from the carvacrol cohort not only harbored two log orders of magnitude lower pathogen loads in their intestines, but also displayed significantly reduced disease symptoms. Alleviated campylobacteriosis following carvacrol application was accompanied by less distinct intestinal apoptosis and pro-inflammatory immune responses as well as by higher numbers of proliferating colonic epithelial cells. Remarkably, the inflammation-ameliorating effects of carvacrol treatment were not restricted to the intestinal tract, but could also be observed in extra-intestinal organs such as liver, kidneys and lungs and, strikingly, systemically as indicated by lower IFN-γ, TNF, MCP-1 and IL-6 serum concentrations in carvacrol versus placebo treated mice. Furthermore, carvacrol treatment was associated with less frequent translocation of viable C. jejuni originating from the intestines to extra-intestinal compartments. Conclusion: The lowered C. jejuni loads and alleviated symptoms observed in the here applied clinical murine model for human campylobacteriosis highlight the application of carvacrol as a promising novel option for both, the treatment of campylobacteriosis and hence, for prevention of post-infectious sequelae in humans, and for the reduction of C. jejuni colonization in the intestines of vertebrate lifestock animals.

show abstract

Section: Discussionmentioning

confidence: 96%

Carvacrol ameliorates acute campylobacteriosis in a clinical murine infection model

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Mice were anesthetized with isoflurane (2%) (24), and LPS was intratracheally instilled (Serotype 026:B6/L3755; Sigma‐Aldrich, St. Louis, MO, USA). Each animal received 50 μl of an LPS solution (5 mg/kg) (16). The control group received an intratracheal instillation of the same volume of saline.…”

Section: Methodsmentioning

confidence: 99%

Acute lung injury is reduced by the α7nAChR agonist PNU‐282987 through changes in the macrophage profile

et al. 2016

View full text Add to dashboard Cite

Nicotinic α-7 acetylcholine receptor (nAChRα7) is a critical regulator of cholinergic anti-inflammatory actions in several diseases, including acute respiratory distress syndrome (ARDS). Given the potential importance of α7nAChR as a therapeutic target, we evaluated whether PNU-282987, an α7nAChR agonist, is effective in protecting the lung against inflammation. We performed intratracheal instillation of LPS to generate acute lung injury (ALI) in C57BL/6 mice. PNU-282987 treatment, either before or after ALI induction, reduced neutrophil recruitment and IL-1β, TNF-α, IL-6, keratinocyte chemoattractant (KC), and IL-10 cytokine levels in the bronchoalveolar lavage fluid (P< 0.05). In addition, lung NF-κB phosphorylation decreased, along with collagen fiber deposition and the number of matrix metalloproteinase-9 and -2 cells, whereas the number of tissue inhibitor of metalloproteinase-1 cells increased (P < 0.05). PNU-282987 treatment also reduced lung mRNA levels and the frequency of M1 macrophages, whereas cells expressing the M2-related markers CD206 and IL-10 increased, suggesting changes in the macrophage profile. Finally, PNU-282987 improved lung function in LPS-treated animals. The collective results suggest that PNU-282987, an agonist of α7nAChR, reduces LPS-induced experimental ALI, thus supporting the notion that drugs that act on α7nAChRs should be explored for ARDS treatment in humans.-Pinheiro, N. M., Santana, F. P. R., Almeida, R. R., Guerreiro, M., Martins, M. A., Caperuto, L. C., Câmara, N. O. S., Wensing, L. A., Prado, V. F., Tibério, I. F. L. C., Prado, M. A. M., Prado, C. M. Acute lung injury is reduced by the α7nAChR agonist PNU-282987 through changes in the macrophage profile.

show abstract

“…Previous research has showed that treatment with rutin possesses the cardioprotective function of antioxidant effect and alteration of TNF-α level in diabetic rats (Saklani et al, 2016). In LPS-induced sepsis, treatment with rutin can improve acute lung injury via inhibition of oxidative stress and inflammatory response, which is characterized by increasing the activity of SOD and CAT, and inhibiting the level of TNF-α and IL-1β (Yeh et al, 2014;Chen et al, 2014;Feng et al, 2014). Thus, we assumed that rutin had a cardioprotective function against sepsis because of its antioxidant and anti-inflammatory properties.…”

Section: Introductionmentioning

confidence: 99%

Protective effects of rutin on lipopolysaccharide-induced heart injury in mice

Xianchu¹,

Zheng²,

Liu³

et al. 2018

J. Toxicol. Sci.

View full text Add to dashboard Cite

Rutin has a wide range of beneficial health properties in the amelioration of multi-organ injury owing to its various biological effects. The aim of this study was to investigate the effects of rutin on lipopolysaccharide (LPS)-induced heart injury and clarify its potential cardioprotective mechanism. The mouse model of heart injury was intraperitoneal infection with LPS, and rutin was orally administered for 8 consecutive days. One day after LPS injection, heart histopathology, cardiac marker enzymes and cardiac fibrosis related genes were determined to evaluate the cardioprotective effects of rutin. In addition, oxidative parameters and inflammatory cytokines were tested to explore its possible underlying mechanism. The presented results showed that rutin significantly improved morphological changes of myocardium and relieved cardiac marker enzymes [creatine kinase (CK) and lactate dehydrogenase (LDH)] level to protect heart in LPS-induced sepsis. And more, rutin observably mitigated fibrosis related genes [matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9)] expression in the heart to prevent against LPS-induced cardiac fibrosis. In addition, rutin markedly increased antioxidant enzymes [superoxide dismutase (SOD) and catalase (CAT)] activity, and improved oxidative production [malondialdehyde (MDA) and HO] level to balance the oxidation and anti-oxidation systems in the heart. Lastly, rutin dramatically ameliorated [tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6)] activity to restrain inflammatory responses in the heart. In conclusion, rutin possessed anti-oxidant and anti-inflammatory properties to improve LPS-induced heart injury, which suggested rutin could be used as a potential cardioprotective medicine in sepsis.

show abstract

Protective Effect of Carvacrol on Acute Lung Injury Induced by Lipopolysaccharide in Mice

Cited by 41 publications

References 25 publications

Carvacrol ameliorates acute campylobacteriosis in a clinical murine infection model

Carvacrol ameliorates acute campylobacteriosis in a clinical murine infection model

Acute lung injury is reduced by the α7nAChR agonist PNU‐282987 through changes in the macrophage profile

Protective effects of rutin on lipopolysaccharide-induced heart injury in mice

Contact Info

Product

Resources

About